Market Research Report Store Contact Dermatitis-Global API Manufacturers, Marke | Page 2

• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across
the globe.
• Product profiles for marketed products for Contact Dermatitis with complete description of
mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Contact Dermatitis drugs in the United States, Europe and Asian
Regions with location details.
• Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Contact
Dermatitis drugs.
• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Contact
Dermatitis drugs.
• Coverage of Contact Dermatitis Phase III pipeline products featuring sections on product description,
mechanism of action, Chemical details and research & development progress.
• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
• Key discontinued Marketed products.
• Global Sales Figure to 2018.
Reasons to buy
• Evaluate the marketing status and exclusivity details of Contact Dermatitis key products to exploit
opportunities for generic drug development opportunities.
• Identify and understand important and diverse types of therapeutics under Phase III development for
Contact Dermatitis.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry
details and exclusivity with respect to Contact Dermatitis.
• API intelligence over marketed drugs forContact Dermatitisand gaining primary intelligence over
active ingredients manufacturers across the globe.
• API intelligence over leading Phase III Pipeline drugs.
• Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to
enhance and expand business potential and scope.